Central Nervous System Lymphoma: Characteristic Findings on Traditional and Advanced Imaging

References

1. 1.↵
   1. Wong ET

   . Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities. Clin Cancer Res 2005; 11: 7151s– 57s

   Abstract/FREE Full Text
2. 2.↵
   1. Mohile NA,
   2. Abrey LE

   . Primary central nervous system lymphoma. Semin Radiat Oncol 2007; 17: 223– 29

   CrossRefPubMed
3. 3.↵
   1. Hill QA,
   2. Owen RG

   . CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319– 32

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Montoto S,
   2. Lister TA

   . Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol Oncol Clin North Am 2005; 19: 751– 63

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Haldorsen IS,
   2. Krossnes BK,
   3. Aarseth JH,
   4. et al

   . Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989–2003: time trends in a 15-year national survey. Cancer 2007; 110: 1803– 14

   CrossRefPubMed
6. 6.↵
   1. van der Sanden GA,
   2. Schouten LJ,
   3. van Dijck JA,
   4. et al

   . Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 2002; 94: 1548– 56

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Olson JE,
   2. Janney CA,
   3. Rao RD,
   4. et al

   . The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95: 1504– 10

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Cote TR,
   2. Manns A,
   3. Hardy CR,
   4. et al

   . Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome: AIDS/Cancer Study Group. J Natl Cancer Inst 1996; 88: 675– 79

   Abstract/FREE Full Text
9. 9.↵
   1. Kasamon YL,
   2. Ambinder RF

   . AIDS-related primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 665– 87

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Diamond C,
    2. Taylor TH,
    3. Aboumrad T,
    4. et al

    . Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006; 106: 128– 35

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Besson C,
    2. Goubar A,
    3. Gabarre J,
    4. et al

    . Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339– 44

    Abstract/FREE Full Text
12. 12.↵
    1. Haldorsen IS,
    2. Espeland A,
    3. Larsen JL,
    4. et al

    . Diagnostic delay in primary central nervous system lymphoma. Acta Oncol 2005; 44: 728– 34

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Morris PG,
    2. Abrey LE

    . Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 2009; 8: 581– 92

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Haldorsen IS,
    2. Krakenes J,
    3. Krossnes BK,
    4. et al

    . CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989–2003. AJNR Am J Neuroradiol 2009; 30: 744– 51

    Abstract/FREE Full Text
15. 15.↵
    1. Buhring U,
    2. Herrlinger U,
    3. Krings T,
    4. et al

    . MRI features of primary central nervous system lymphomas at presentation. Neurology 2001; 57: 393– 96

    Abstract/FREE Full Text
16. 16.↵
    1. Senocak E,
    2. Oguz KK,
    3. Ozgen B,
    4. et al

    . Parenchymal lymphoma of the brain on initial MR imaging: a comparative study between primary and secondary brain lymphoma. Eur J Radiol 2010 Mar 2. [Epub ahead of print]
17. 17.↵
    1. Bierman P,
    2. Giglio P

    . Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2005; 19: 597– 609

    CrossRefPubMedWeb of Science
18. 18.↵
    1. DeAngelis LM,
    2. Boutros D

    . Leptomeningeal metastasis. Cancer Invest 2005; 23: 145– 54

    CrossRefPubMedWeb of Science
19. 19.↵
    1. van Oostenbrugge RJ,
    2. Twijnstra A

    . Presenting features and value of diagnostic procedures in leptomeningeal metastases. Neurology 1999; 53: 382– 85

    Abstract/FREE Full Text
20. 20.↵
    1. Freilich RJ,
    2. Krol G,
    3. DeAngelis LM

    . Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38: 51– 57

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Gleissner B,
    2. Chamberlain M

    . Treatment of CNS dissemination in systemic lymphoma. J Neurooncol 2007; 84: 107– 17

    CrossRefPubMed
22. 22.↵
    1. Fitzsimmons A,
    2. Upchurch K,
    3. Batchelor T

    . Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am 2005; 19: 689– 703

    CrossRefPubMed
23. 23.↵
    1. Eichler AF,
    2. Batchelor TT

    . Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 2006; 21: E15

    PubMed
24. 24.↵
    1. Koeller KK,
    2. Smirniotopoulos JG,
    3. Jones RV

    . Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics 1997; 17: 1497– 526

    PubMedWeb of Science
25. 25.↵
    1. Go JL,
    2. Lee SC,
    3. Kim PE

    . Imaging of primary central nervous system lymphoma. Neurosurg Focus 2006; 21: E4

    PubMed
26. 26.↵
    1. Gliemroth J,
    2. Kehler U,
    3. Gaebel C,
    4. et al

    . Neuroradiological findings in primary cerebral lymphomas of non-AIDS patients. Clin Neurol Neurosurg 2003; 105: 78– 86

    CrossRefPubMed
27. 27.↵
    1. Coulon A,
    2. Lafitte F,
    3. Hoang-Xuan K,
    4. et al

    . Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 2002; 12: 329– 40

    CrossRefPubMed
28. 28.↵
    1. Thurnher MM,
    2. Rieger A,
    3. Kleibl-Popov C,
    4. et al

    . Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings. Neuroradiology 2001; 43: 29– 35

    CrossRefPubMed
29. 29.↵
    1. Kuker W,
    2. Nagele T,
    3. Korfel A,
    4. et al

    . Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 2005; 72: 169– 77

    CrossRefPubMed
30. 30.↵
    1. Weaver JD,
    2. Vinters HV,
    3. Koretz B,
    4. et al

    . Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist 2007; 13: 150– 53

    CrossRefPubMed
31. 31.↵
    1. Fine HA,
    2. Mayer RJ

    . Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093– 104

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Hayakawa T,
    2. Takakura K,
    3. Abe H,
    4. et al

    . Primary central nervous system lymphoma in Japan: a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994; 19: 197– 215

    CrossRefPubMed
33. 33.↵
    1. Schlegel U,
    2. Schmidt-Wolf IG,
    3. Deckert M

    . Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci 2000; 181: 1– 12

    CrossRefPubMed
34. 34.↵
    1. Erdag N,
    2. Bhorade RM,
    3. Alberico RA,
    4. et al

    . Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 2001; 176: 1319– 26

    CrossRefPubMed
35. 35.↵
    1. Bataille B,
    2. Delwail V,
    3. Menet E,
    4. et al

    . Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000; 92: 261– 66

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Gunduz K,
    2. Pulido JS,
    3. McCannel CA,
    4. et al

    . Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus 2006; 21: E9

    PubMed
37. 37.↵
    1. Kuker W,
    2. Herrlinger U,
    3. Gronewaller E,
    4. et al

    . Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging? J Neurol 2002; 249: 1713– 16

    CrossRefPubMed
38. 38.↵
    1. Iwamoto FM,
    2. Abrey LE

    . Primary dural lymphomas: a review. Neurosurg Focus 2006; 21: E5

    PubMed
39. 39.↵
    1. Haldorsen IS,
    2. Krakenes J,
    3. Goplen AK,
    4. et al

    . AIDS-related primary central nervous system lymphoma: a Norwegian national survey 1989–2003. BMC Cancer 2008; 8: 225

    CrossRefPubMed
40. 40.↵
    1. Calli C,
    2. Kitis O,
    3. Yunten N,
    4. et al

    . Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006; 58: 394– 403

    CrossRefPubMed
41. 41.↵
    1. Hartmann M,
    2. Heiland S,
    3. Harting I,
    4. et al

    . Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett 2003; 338: 119– 22

    CrossRefPubMedWeb of Science
42. 42.↵
    1. Harting I,
    2. Hartmann M,
    3. Jost G,
    4. et al

    . Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett 2003; 342: 163– 66

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Taillibert S,
    2. Guillevin R,
    3. Menuel C,
    4. et al

    . Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol 2008; 86: 225– 29

    CrossRefPubMed
44. 44.
    1. Zacharia TT,
    2. Law M,
    3. Naidich TP,
    4. et al

    . Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging 2008; 18: 411– 17

    CrossRefPubMedWeb of Science
45. 45.
    1. Schroeder PC,
    2. Post MJ,
    3. Oschatz E,
    4. et al

    . Analysis of the utility of diffusion-weighted MRI and apparent diffusion coefficient values in distinguishing central nervous system toxoplasmosis from lymphoma. Neuroradiology 2006; 48: 715– 20

    CrossRefPubMedWeb of Science
46. 46.
    1. Stadnik TW,
    2. Chaskis C,
    3. Michotte A,
    4. et al

    . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings. AJNR Am J Neuroradiol 2001; 22: 969– 76

    Abstract/FREE Full Text
47. 47.
    1. Toh CH,
    2. Castillo M,
    3. Wong AM,
    4. et al

    . Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol 2008; 29: 471– 75

    Abstract/FREE Full Text
48. 48.↵
    1. Barajas RF Jr.,
    2. Rubenstein JL,
    3. Chang JS,
    4. et al

    . Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010; 31: 60– 66. Epub 2009 Sep 3

    Abstract/FREE Full Text
49. 49.↵
    1. Wu O,
    2. Ostergaard L,
    3. Sorensen AG

    . Technical aspects of perfusion-weighted imaging. Neuroimaging Clin N Am 2005; 15: 623– 37, xi

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Cianfoni A,
    2. Colosimo C,
    3. Basile M,
    4. et al

    . Brain perfusion CT: principles, technique and clinical applications. Radiol Med 2007; 112: 1225– 43

    CrossRefPubMedWeb of Science
51. 51.↵
    1. Fainardi E,
    2. Di BF,
    3. Borrelli M,
    4. et al

    . Potential role of CT perfusion parameters in the identification of solitary intra-axial brain tumor grading. Acta Neurochir Suppl 2010; 106: 283– 87

    CrossRefPubMed
52. 52.↵
    1. Hakyemez B,
    2. Erdogan C,
    3. Bolca N,
    4. et al

    . Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 2006; 24: 817– 24

    CrossRefPubMed
53. 53.↵
    1. Larsson HB,
    2. Courivaud F,
    3. Rostrup E,
    4. et al

    . Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 Tesla. Magn Reson Med 2009; 62: 1270– 81

    CrossRefPubMed
54. 54.↵
    1. Kim HS,
    2. Jahng GH,
    3. Ryu CW,
    4. et al

    . Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 2009; 30: 1574– 79

    Abstract/FREE Full Text
55. 55.↵
    1. Peng XH,
    2. Qian X,
    3. Mao H,
    4. et al

    . Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008; 3: 311– 21

    PubMed
56. 56.
    1. Manninger SP,
    2. Muldoon LL,
    3. Nesbit G,
    4. et al

    . An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. AJNR Am J Neuroradiol 2005; 26: 2290– 300

    Abstract/FREE Full Text
57. 57.↵
    1. Bakshi R

    . Neuroimaging of HIV and AIDS related illnesses: a review. Front Biosci 2004; 9: 632– 46

    CrossRefPubMed
58. 58.↵
    1. Chang L,
    2. Ernst T

    . MR spectroscopy and diffusion-weighted MR imaging in focal brain lesions in AIDS. Neuroimaging Clin N Am 1997; 7: 409– 26

    PubMed
59. 59.
    1. Chang L,
    2. Miller BL,
    3. McBride D,
    4. et al

    . Brain lesions in patients with AIDS: H-1 MR spectroscopy. Radiology 1995; 197: 525– 31

    PubMedWeb of Science
60. 60.
    1. Palmedo H,
    2. Urbach H,
    3. Bender H,
    4. et al

    . FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33: 164– 68

    CrossRefPubMed
61. 61.↵
    1. Rosenfeld SS,
    2. Hoffman JM,
    3. Coleman RE,
    4. et al

    . Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33: 532– 36

    Abstract/FREE Full Text
62. 62.
    1. Ogawa T,
    2. Kanno I,
    3. Hatazawa J,
    4. et al

    . Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain. Radiographics 1994; 14: 101– 10

    PubMed
63. 63.
    1. Shinoda J,
    2. Yano H,
    3. Murase S,
    4. et al

    . High 123I-IMP retention on SPECT image in primary central nervous system lymphoma. J Neurooncol 2003; 61: 261– 65

    CrossRefPubMed
64. 64.
    1. Ruiz A,
    2. Ganz WI,
    3. Post MJ,
    4. et al

    . Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol 1994; 15: 1885– 94

    Abstract/FREE Full Text
65. 65.↵
    1. Chen W,
    2. Silverman DH

    . Advances in evaluation of primary brain tumors. Semin Nucl Med 2008; 38: 240– 50

    CrossRefPubMed
66. 66.↵
    1. Heiss WD

    . The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 2009; 36 (suppl 1): S105– 12

    CrossRefPubMed